NEW COST EFFECTIVE HIV MEDICINES WORKING OVER BTH CCR5 & CXCR4 RECEPTOR WHICH BINDS VIRUS T CD4 CELL MAY HIT THE MARKET SOON
- Get link
- Other Apps
NEW COST EFFECTIVE HIV MEDICINES MAY HIT THE MARKET SOON
PROF.DRRAM ,HIV/AIDS,SEX Diseases,Deaddiction & Hepatitis Expert
profdrram@gmail.com,+917838059592,+919832025033,DELHI,INDIA
HIV/ AIDS,CANCER MODERN MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
Since HIV emerged in the '80s, drug 'cocktails' transformed the deadly disease into a manageable one. But the virus is adept at developing resistance to drugs, and treatment regimens require tweaking that can be costly. Now scientists are announcing new progress toward affordable drugs that could potentially thwart the virus's ability to resist them.One drug company (Pfizer) has developed a compound that blocks HIV's interaction with one of those proteins, a co-receptor called CCR5. But the virus can also use a second co-receptor, CXCR4, to enter cells. If a drug targets just CCR5, a more virulent strain that favors CXCR4 could emerge over time, says Liotta of american Chemical society.
In theory, drugs targeting CXCR4 would be an effective addition to the arsenal against HIV. But interfering with that protein, which regulates several of the body's inflammatory responses, could lead to serious side effects."With a chronic infection like HIV, it's very challenging to take a drug every day of your life if you have significant side effects," Liotta says. "This is a very high bar. No drug that functions as a CXCR4 antagonist for HIV has gotten over that bar."Liotta's team decided to search for compounds that might be able to bind both CCR5 and CXCR4 at the same time, while avoiding serious side effects.
"In Lbiratry The agents which were active against CCR5, CXCR4 and HIV reverse transcriptase has been developed ," Liotta says. "That was unprecedented. Also, they don't perturb any of the CXCR4 signaling pathways that lead to inflammation."
An additional benefit of this approach is that the compounds target proteins on human cells. Most HIV drugs target viral proteins, but because they often mutate when exposed to antiretroviral agents, resistance can develop quickly. When that happens, patients have to switch to a new drug combination that can be less effective than the previous treatment. Human proteins rarely mutate to a significant extent, so HIV will be far less likely get around drug combination therapies that include a CXCR4/CCR5 inhibitor, Liotta explains. Since these agents are inexpensive to prepare, they could potentially keep treatment affordable for millions, particularly in the developing world.
profdrram@gmail.com,+917838059592,+919832025033,DELHI,INDIA
HIV/ AIDS,CANCER MODERN MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
Since HIV emerged in the '80s, drug 'cocktails' transformed the deadly disease into a manageable one. But the virus is adept at developing resistance to drugs, and treatment regimens require tweaking that can be costly. Now scientists are announcing new progress toward affordable drugs that could potentially thwart the virus's ability to resist them.One drug company (Pfizer) has developed a compound that blocks HIV's interaction with one of those proteins, a co-receptor called CCR5. But the virus can also use a second co-receptor, CXCR4, to enter cells. If a drug targets just CCR5, a more virulent strain that favors CXCR4 could emerge over time, says Liotta of american Chemical society.
In theory, drugs targeting CXCR4 would be an effective addition to the arsenal against HIV. But interfering with that protein, which regulates several of the body's inflammatory responses, could lead to serious side effects."With a chronic infection like HIV, it's very challenging to take a drug every day of your life if you have significant side effects," Liotta says. "This is a very high bar. No drug that functions as a CXCR4 antagonist for HIV has gotten over that bar."Liotta's team decided to search for compounds that might be able to bind both CCR5 and CXCR4 at the same time, while avoiding serious side effects.
"In Lbiratry The agents which were active against CCR5, CXCR4 and HIV reverse transcriptase has been developed ," Liotta says. "That was unprecedented. Also, they don't perturb any of the CXCR4 signaling pathways that lead to inflammation."
An additional benefit of this approach is that the compounds target proteins on human cells. Most HIV drugs target viral proteins, but because they often mutate when exposed to antiretroviral agents, resistance can develop quickly. When that happens, patients have to switch to a new drug combination that can be less effective than the previous treatment. Human proteins rarely mutate to a significant extent, so HIV will be far less likely get around drug combination therapies that include a CXCR4/CCR5 inhibitor, Liotta explains. Since these agents are inexpensive to prepare, they could potentially keep treatment affordable for millions, particularly in the developing world.
Comments
Post a Comment